N 1 Collaborative Inc
Public records show a registered, tax-exempt organization in good standing.
What it says it does
TO MAKE INDIVIDUALIZED MEDICINES ROUTINELY AND RAPIDLY ACCESSIBLE TO RARE DISEASE PATIENTS WORLDWIDE.
- Income
- $894,517
- Spending
- $323,892
- Spent on programs
- 56%
- Reserves
- 25.6 months of spending
- Largest source of income
- donations and private grants, 100%
- Employees
- 2
- Volunteers
- 60
Source: Form 990 for the year ending December 31, 2025, filed with the Internal Revenue Service. Rating method 2026.2. How we rate
Financial health
Strong: 93 out of 100. Higher than 69% of charities in its peer group (diseases, $250k to $1m).
Reserves
35 of 35Spendable reserves would cover 25.6 months of spending.
Debt
20 of 20It owes 1% of what it owns.
Living within its means
15 of 15Income exceeded spending by 64% of income.
Income trend
15 of 15Income rose 97% on the year before.
Spending floor
8 of 1556% of spending went to programs and raising each dollar of donations cost 5 cents.
Source: Form 990 for the year ending December 31, 2025, filed with the Internal Revenue Service. Rating method 2026.2. How we rate
Governance
Strong: 91 out of 100. Higher than 73% of charities in its peer group (diseases, $250k to $1m).
Independent board
25 of 256 of 6 voting board members are independent.
Conflict of interest policy
15 of 15Has a written conflict of interest policy.
Whistleblower policy
8 of 8Has a written whistleblower policy.
Record keeping policy
7 of 7Has a written policy on keeping and destroying records.
Board minutes
5 of 5Keeps minutes of board meetings.
Board sees the tax return
10 of 10Gave the board a copy of this return before filing it.
Independent check of accounts
6 of 15Its accounts were not audited or reviewed by an independent accountant.
No reported misuse
10 of 10Reports no diversion of assets, excess benefits or loans to insiders.
Source: Form 990 for the year ending December 31, 2025, filed with the Internal Revenue Service. Rating method 2026.2. How we rate
Impact evidence
Describes programs. Its tax return describes what it does but we have found no measurable results in it.
Programs described in its return (3)
- $72,653 spent. IN 2025, THE ORGANIZATION LAUNCHED TWO OPENLY ACCESSIBLE DATABASES TO SERVE PATIENTS, FAMILIES, RESEARCHERS, AND CLINICIANS WORKING IN THE INDIVIDUALIZED MEDICINE SPACE. THE GENE REGISTRY CATALOGS N-OF-1 PROJECTS, ASSESSED VARIANTS, AND MARKETED GENETIC THERAPIES, PROVIDING A CENTRALIZED RESOURCE TO ADVANCE AWARENESS AND KNOWLEDGE-SHARING ACROSS THE INDIVIDUALIZED MEDICINE FIELD. THE CONNECTIONS PLATFORM ENABLES PEER-TO- PEER NETWORKING ACROSS THE RARE DISEASE COMMUNITY, LINKING PATIENTS AND FAMILIES WITH ONE ANOTHER AS WELL AS WITH RESEARCHERS AND CLINICIANS WORKING ON RELEVANT CONDITIONS, AND HAS GROWN TO MORE THAN 400 COMMUNITY MEMBERS SINCE ITS LAUNCH. BOTH PLATFORMS ARE DESIGNED TO REDUCE THE INFORMATION AND ISOLATION BARRIERS THAT CHARACTERIZE ULTRA-RARE DISEASE. THE ULTIMATE BENEFICIARIES ARE PATIENTS WITH ULTRA-RARE GENETIC CONDITIONS AND THEIR FAMILIES, WHO GAIN ACCESS TO CRITICAL SCIENTIFIC INFORMATION AND A COMMUNITY OF INDIVIDUALS AND EXPERTS WHO CAN SUPPORT THEIR PATH TOWARD TREATMENT. IN 2025, THE ORGANIZATION LAUNCHED TWO OPENLY ACCESSIBLE DATABASES TO SERVE PATIENTS, FAMILIES, RESEARCHERS, AND CLINICIANS WORKING IN THE INDIVIDUALIZED MEDICINE SPACE. THE GENE REGISTRY CATALOGS N-OF-1 PROJECTS, ASSESSED VARIANTS, AND MARKETED GENETIC THERAPIES, PROVIDING A CENTRALIZED RESOURCE TO ADVANCE AWARENESS AND KNOWLEDGE-SHARING ACROSS THE INDIVIDUALIZED MEDICINE FIELD. THE CONNECTIONS PLATFORM ENABLES PEER-TO- PEER NETWORKING ACROSS THE RARE DISEASE COMMUNITY, LINKING PATIENTS AND FAMILIES WITH ONE ANOTHER AS WELL AS WITH RESEARCHERS AND CLINICIANS WORKING ON RELEVANT CONDITIONS, AND HAS GROWN TO MORE THAN 400 COMMUNITY MEMBERS SINCE ITS LAUNCH. BOTH PLATFORMS ARE DESIGNED TO REDUCE THE INFORMATION AND ISOLATION BARRIERS THAT CHARACTERIZE ULTRA-RARE DISEASE. THE ULTIMATE BENEFICIARIES ARE PATIENTS WITH ULTRA-RARE GENETIC CONDITIONS AND THEIR FAMILIES, WHO GAIN ACCESS TO CRITICAL SCIENTIFIC INFORMATION AND A COMMUNITY OF INDIVIDUALS AND EXPERTS WHO CAN SUPPORT THEIR PATH TOWARD TREATMENT.
- $64,432 spent. THE ORGANIZATION HOSTED ITS ANNUAL MEETING AND A SERIES OF VIRTUAL SEMINARS IN 2025, EACH REACHING BETWEEN 100 AND 200 PARTICIPANTS ACROSS THE INDIVIDUALIZED MEDICINE ECOSYSTEM INCLUDING RESEARCHERS, CLINICIANS, PATIENT ADVOCATES, INDUSTRY REPRESENTATIVES, AND FAMILIES OF AFFECTED PATIENTS. EVENTS FEATURED SPEAKERS, PANELS, AND WORKSHOPS FOCUSED ON BEST PRACTICES, COMMUNITY UPDATES, AND FIELD-WIDE STRATEGY FOR ADVANCING INDIVIDUALIZED MEDICINES FOR ULTRA-RARE GENETIC CONDITIONS. BY CONVENING CROSS-SECTOR STAKEHOLDERS IN BOTH IN-PERSON AND VIRTUAL FORMATS, N1C'S CONFERENCES AND SEMINARS ACCELERATE KNOWLEDGE EXCHANGE, FOSTER COLLABORATION, AND BUILD THE SHARED INFRASTRUCTURE NEEDED TO MAKE INDIVIDUALIZED TREATMENTS MORE ROUTINELY AND RAPIDLY ACCESSIBLE TO PATIENTS. THE ORGANIZATION HOSTED ITS ANNUAL MEETING AND A SERIES OF VIRTUAL SEMINARS IN 2025, EACH REACHING BETWEEN 100 AND 200 PARTICIPANTS ACROSS THE INDIVIDUALIZED MEDICINE ECOSYSTEM INCLUDING RESEARCHERS, CLINICIANS, PATIENT ADVOCATES, INDUSTRY REPRESENTATIVES, AND FAMILIES OF AFFECTED PATIENTS. EVENTS FEATURED SPEAKERS, PANELS, AND WORKSHOPS FOCUSED ON BEST PRACTICES, COMMUNITY UPDATES, AND FIELD-WIDE STRATEGY FOR ADVANCING INDIVIDUALIZED MEDICINES FOR ULTRA-RARE GENETIC CONDITIONS. BY CONVENING CROSS-SECTOR STAKEHOLDERS IN BOTH IN-PERSON AND VIRTUAL FORMATS, N1C'S CONFERENCES AND SEMINARS ACCELERATE KNOWLEDGE EXCHANGE, FOSTER COLLABORATION, AND BUILD THE SHARED INFRASTRUCTURE NEEDED TO MAKE INDIVIDUALIZED TREATMENTS MORE ROUTINELY AND RAPIDLY ACCESSIBLE TO PATIENTS.
- $43,592 spent. THE ORGANIZATION CONVENES OPEN, CROSS-DISCIPLINARY WORKGROUPS THAT BRING TOGETHER RESEARCHERS, CLINICIANS, AND RARE DISEASE STAKEHOLDERS TO DEVELOP SHARED FRAMEWORKS AND CONSENSUS RESOURCES FOR THE INDIVIDUALIZED MEDICINE FIELD. IN 2025, THE WORKGROUPS PROGRAM PRODUCED CONSENSUS GUIDELINES FOR ASSESSING THE ELIGIBILITY OF PATHOGENIC DNA VARIANTS FOR ANTISENSE OLIGONUCLEOTIDE (ASO) TREATMENTS. WORKGROUPS AND THEIR OUTPUTS ARE OPENLY ACCESSIBLE TO THE BROADER RARE DISEASE COMMUNITY, REACHING MORE THAN 1,000 COMMUNITY MEMBERS INCLUDING RESEARCHERS, CLINICIANS, AND PATIENT ADVOCATES. THE ULTIMATE BENEFICIARIES ARE PATIENTS WITH ULTRA-RARE GENETIC CONDITIONS, WHO GAIN ACCESS TO BETTER-INFORMED CLINICIANS AND RESEARCHERS EQUIPPED WITH SHARED STANDARDS TO EVALUATE AND ADVANCE INDIVIDUALIZED TREATMENT OPTIONS.
Source: Form 990 for the year ending December 31, 2025, filed with the Internal Revenue Service. Rating method 2026.2. How we rate
Legitimacy checks
Is it registered with the IRS? Passed.
Listed in the IRS master file of tax-exempt organizations as a 501(c)(3) charitable organization.
Source: Exempt Organizations Business Master File, Internal Revenue Service, file dated October 13, 2026.
Has the IRS revoked its tax-exempt status? Passed.
Not on the IRS automatic revocation list.
Source: Automatic revocation of exemption list, Internal Revenue Service, file dated October 13, 2026.
Are donations tax-deductible? Passed.
On the IRS list of organizations eligible to receive tax-deductible contributions.
Source: Publication 78 data: organizations eligible for tax-deductible contributions, Internal Revenue Service, file dated October 13, 2026.
Is it keeping up with its IRS filings? Passed.
Most recent return on file covers the year ending December 2025.
Source: Exempt Organizations Business Master File, Internal Revenue Service, file dated October 13, 2026.
How long has it been tax-exempt? Passed.
Recognized by the IRS since April 2024.
Source: Exempt Organizations Business Master File, Internal Revenue Service, file dated October 13, 2026.
Is it in good standing with state regulators? Passed.
Not on California's list of charities barred from soliciting. Other states are not yet checked.
Source: May Not Operate or Solicit for Charitable Purposes list, California Attorney General, Registry of Charities and Fundraisers, file dated October 21, 2026.
Ratings and checks are our reading of public records, using the published method. They are not a statement about anyone's honesty. If you work for this organization, you can send corrections or results, confirm you want gifts through Veridonate, or ask to be removed from giving.